PF-ILD associated with surgical pulmonary activation is a dubious disease in the field of infectious respiratory digestive and endocrine disorders. Clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized clinical treatment are essential for improving prognosis.
The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PF-ILD associated with surgical pulmonary activation requires individualized development of treatment programs, which typically include drug therapy, rehabilitation interventions, and regular follow-up management.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD surgical pulmonary biopsies.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.